Abstract
Systemic anticancer therapies may produce several toxicities including eye adverse events. In fact, contrary to general belief, the eye is a really sensitive organ. These adverse events may vary between a simple lacrimation to a marked irreversible visual loss even at therapeutic doses. A review of the literature was conducted showing that ocular toxicity is not as uncommon as previously thought and unfortunately in most cases, the mechanism underlying this continue to be poorly understood. Dealing with this toxicity is relevant and a close collaboration between oncologists, ophthalmologists and pharmacists would be advisable to reduce the incidence of serious toxicities.
Keywords: Ocular toxicity, chemotherapy toxicity, epiphora, excessive lacrimation.
Current Cancer Therapy Reviews
Title:Ocular Toxicities in Cancer Therapy: Still Overlooked
Volume: 10 Issue: 1
Author(s): Esther Una Cidon and Pilar Alonso
Affiliation:
Keywords: Ocular toxicity, chemotherapy toxicity, epiphora, excessive lacrimation.
Abstract: Systemic anticancer therapies may produce several toxicities including eye adverse events. In fact, contrary to general belief, the eye is a really sensitive organ. These adverse events may vary between a simple lacrimation to a marked irreversible visual loss even at therapeutic doses. A review of the literature was conducted showing that ocular toxicity is not as uncommon as previously thought and unfortunately in most cases, the mechanism underlying this continue to be poorly understood. Dealing with this toxicity is relevant and a close collaboration between oncologists, ophthalmologists and pharmacists would be advisable to reduce the incidence of serious toxicities.
Export Options
About this article
Cite this article as:
Cidon Una Esther and Alonso Pilar, Ocular Toxicities in Cancer Therapy: Still Overlooked, Current Cancer Therapy Reviews 2014; 10 (1) . https://dx.doi.org/10.2174/157339471001140815152249
DOI https://dx.doi.org/10.2174/157339471001140815152249 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pathogenesis, Experimental Models and Contemporary Pharmacotherapy of Irritable Bowel Syndrome: Story About the Brain-Gut Axis
Current Neuropharmacology New Platinum and Ruthenium Complexes - the Latest Class of Potential Chemotherapeutic Drugs - a Review of Recent Developments in the Field
Mini-Reviews in Medicinal Chemistry Design of Telomerase Inhibitors for the Treatment of Cancer
Current Pharmaceutical Design A Review on Theragnostic Applications of Micrornas and Long Non- Coding RNAs in Colorectal Cancer
Current Topics in Medicinal Chemistry Progresses in TCM Metal-Based Antitumour Agents
Anti-Cancer Agents in Medicinal Chemistry Chemopreventive Properties of Peptide Lunasin: A Review
Protein & Peptide Letters Recent Advances in Prostate-Specific Membrane Antigen-Based Radiopharmaceuticals
Current Topics in Medicinal Chemistry Targeting Epidermal Growth Factor Receptor in Solid Tumors: Critical Evaluation of the Biological Importance of Therapeutic Monoclonal Antibodies
Current Medicinal Chemistry 5-Fluorouracil Derivatives Induce Differentiation Mediated by Tubulin and HLA Class I Modulation
Medicinal Chemistry Transmission Electron Microscopy as Key Technique for the Characterization of Telocytes
Current Stem Cell Research & Therapy The mTOR/4E-BP1/eIF4E Signalling Pathway as a Source of Cancer Drug Targets
Current Medicinal Chemistry Meet Our Editorial Board Member: Major Academic/Scientific Achievements
Current Cancer Drug Targets Subtype-Selective Dopamine Receptor Radioligands for PET Imaging: Current Status and Recent Developments
Current Medicinal Chemistry A Novel Lily-of-the-Valley Fragrance Contrast Agent for Magnetic Resonance and Fluorescence Imaging of Prostate Cancer Cells
Current Pharmaceutical Biotechnology Natural Flora and Anticancer Regime: Milestones and Roadmap
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Current Medicinal Chemistry Role of Phase II Drug Metabolizing Enzymes in Cancer Chemoprevention
Current Drug Metabolism A Qualitative and Quantitative Study of the Innervation of the Human Non Pregnant Uterus
Current Protein & Peptide Science Urinary Tract Tumors, Biology and Risk for Artificial Sweeteners Use with Particular Emphasis on some South American Countries
Current Nutrition & Food Science Cell Cycle and Cancer: The G1 Restriction Point and the G1 / S Transition
Current Genomics